Abstract LB166: OP-3136, a selective KAT6 inhibitor, demonstrates anti-tumor activity in prostate, ovarian, and non-small cell lung cancer preclinical models

前列腺 癌症研究 卵巢癌 前列腺癌 医学 癌症 肺 内科学
作者
Gopinath S. Palanisamy,Susanna A. Barratt,Chelsea L. Hope,Srinivasan Jayaraman,Brandon Robello,Guadalupe Peña,Raymond A. Ng,David C. Myles
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:85 (8_Supplement_2): LB166-LB166 被引量:3
标识
DOI:10.1158/1538-7445.am2025-lb166
摘要

Histone lysine acetyltransferases KAT6A and KAT6B are frequently dysregulated in cancer and are mechanistically linked to key oncogenic processes. Small-molecule inhibitors of KAT6 have shown promising clinical efficacy, particularly in ER/HER2- metastatic breast cancer. However, KAT6 inhibitors remain largely unexplored in other solid tumors despite strong biological and mechanistic rationale for KAT6 as a potential target. Here, we report for the first time that the inhibition of KAT6 using OP-3136, a highly selective KAT6 inhibitor currently in Phase 1 clinical trials, demonstrates robust anti-tumor activity in preclinical models of prostate cancer, ovarian cancer, and non-small cell lung cancer (NSCLC), both in vitro and in vivo. In vitro proliferation assays were conducted on KAT6A-expressing or overexpressing cell lines: VCAP (prostate cancer), OAW28 (ovarian cancer, KAT6A-amplified), OVCAR3 (ovarian cancer), and LCLC-97TM1 (NSCLC). In vivo efficacy was evaluated in xenograft models using OVCAR3 and LCLC-97TM1 cells in immunocompromised mice.OP-3136 inhibited proliferation across all tested prostate cancer, ovarian cancer and NSCLC cell lines. In the OVCAR3 xenograft ovarian cancer model, oral administration of OP-3136 as monotherapy at 0.5 and 1 mg/kg resulted in tumor regression with tumor growth inhibition (TGI) of 104.5% and 105.4%, respectively. In the LCLC-97TM1 NSCLC xenograft model, monotherapy with OP-3136 at 1 mg/kg achieved a TGI of 62%. These findings highlight the potential of OP-3136 monotherapy to treat prostate, ovarian, and NSCLC tumors and strongly support expanding the clinical investigation of KAT6 inhibitors beyond ER+/HER2- breast cancer. Citation Format: Gopinath S. Palanisamy, Susanna A. Barratt, Chelsea Hope, Srinivasan Jayaraman, Brandon Robello, Guadalupe Peña, Raymond A. Ng, David C. Myles. OP-3136, a selective KAT6 inhibitor, demonstrates anti-tumor activity in prostate, ovarian, and non-small cell lung cancer preclinical models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_2):Abstract nr LB166.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
研友_Ze2V48完成签到,获得积分10
1秒前
8mian发布了新的文献求助10
1秒前
wanci的应助被蕾先生采纳,获得10
1秒前
1秒前
科研通AI6.2的应助被yinyinyin采纳,获得10
1秒前
shaco发布了新的文献求助10
1秒前
xixi发布了新的文献求助10
2秒前
2秒前
奔跑少年完成签到,获得积分10
2秒前
小厂面完成签到,获得积分10
2秒前
NN发布了新的文献求助30
3秒前
3秒前
shaangu623发布了新的文献求助30
4秒前
4秒前
烟花的应助被楠楠采纳,获得10
4秒前
入司的应助被吱吱采纳,获得10
4秒前
植保匠人发布了新的文献求助100
4秒前
刘鑫如完成签到,获得积分10
5秒前
羞涩的诗柳完成签到,获得积分10
5秒前
黑质发布了新的文献求助10
6秒前
SciGPT的应助被hmy采纳,获得10
6秒前
6秒前
6秒前
6秒前
chen发布了新的文献求助10
7秒前
sssss发布了新的文献求助10
7秒前
7秒前
奔跑少年发布了新的文献求助10
8秒前
顾矜的应助被无语的安露采纳,获得10
8秒前
shaco完成签到,获得积分10
9秒前
狂野的不正完成签到,获得积分20
9秒前
大面包完成签到,获得积分10
9秒前
10秒前
10秒前
小马甲的应助被顾北采纳,获得10
11秒前
深情安青的应助被顾北采纳,获得10
11秒前
思源的应助被顾北采纳,获得10
11秒前
斯文败类的应助被顾北采纳,获得10
11秒前
李爱国的应助被顾北采纳,获得10
11秒前
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188118
求助须知:如何正确求助?哪些是违规求助? 9575977
关于积分的说明 21844428
捐赠科研通 7785918
什么是DOI,文献DOI怎么找? 3435205
关于科研通互助平台的介绍 2559558
邀请新用户注册赠送积分活动 2482065